Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Board of directors
According to the articles of association the board of directors shall consist of at least three (3) and at most eight (8) board members without deputies. Mendus’ board of directors currently consists of six (6) board members, including the chairman of the board of directors. All board members have been appointed until the end of next annual general meeting.
For information regarding the board’s work and remuneration, please refer to the company’s corporate governance report.
Chairman since 2021
MBA in Finance and Management from Columbia Business School
Shares: 80,000 (through related)
Experience: Christine Lind is an American citizen, born in 1974. Christine Lind holds a bachelor’s degree in finance and information system from New York University, Stern School of Business, and an MBA-degree in finance and management from Columbia Business School. Christine Lind has extensive experience from management roles in the global biotech industry (e.g. Vice President Business Development at LifeCell Corporation and Executive Vice President Business Development and subsequently CEO of Medivir AB) and as a strategic and financial advisor to biotech and pharmaceutical companies (at Merrill Lynch & Co). Christine Lind is currently a board member of Xspray Pharma AB, CEO and chairman of the board of directors of Lind Growth Strategy AB and Vice President, Commercial of NDA Group AB.
Ongoing engagements: Board member of Xspray Pharma AB, CEO and chairman of the board of directors of Lind Growth Strategy AB and Vice President, Commercial of NDA Group AB
Independency: Christine Lind is independent in relation to the company, its senior executives and major shareholders.
Andrea van Elsas
Board Member since 2021
Ph.D. in Immunology and Oncology and an M.S. in Molecular and Cell Biology
Experience: Andrea van Elsas has previously served as Chief Scientific Officer at Aduro Biotech, following the acquisition of BioNovion, a company he co-founded in 2011, and held various positions at Organon (acquired by Schering-Plough and later by Merck) in The Netherlands and Cambridge, Massachusetts, US. While working for Organon and Schering-Plough, he directed the immuno-oncology portfolio and led the anti-PD1 program that later became known as pembrolizumab. As a postdoctoral researcher, he worked in the lab of 2018 Nobel Laureate Jim Allison at the University of California, Berkeley and is a co-inventor on the original anti-CTLA-4 patents that formed the basis for the development of ipilimumab, the first checkpoint inhibitor approved in 2011 by the FDA for the treatment of melanoma.
Ongoing assignments: Partner with Third Rock Ventures, Interim CSO at Abata Therapeutics, Supervisory Board member at InteRNA Technologies, Scientific Advisory Board member at Lava Therapeutics (Chair).
Independency:Andrea van Elsas is independent in relation to the company, its senior executives, and major shareholders.
Board Member since 2021
Ph.D. in Biochemistry and a M.B.A. from the Rotterdam School of Management
Experience: Hans Preusting has previously served as the Chief Business Officer and interim COO of uniQure. Prior to that he was the VP of Process Development and Manufacturing at AMT, the predecessor of uniQure. Hans now works as an independent consultant for several biotech companies and is co-founder of two biotech start-up companies. He holds two patents and has published over 20 scientific articles. His expertise is focused on business development, product development and manufacturing. He earned a Ph.D. in biochemistry from the University of Groningen, the Netherlands and an M.B.A. from the Rotterdam School of Management, the Netherlands.
Ongoing engagements: Dr. Preusting is currently CEO of Synerkine Pharma B.V. and CDO of DegenRx B.V.
Independency: Hans Preusting is independent in relation to the company, its senior executives, and major shareholders.
Board Member since 2021
Master’s degree in Business Economics, master’s degree cum laude in Aerospace Engineering
Experience: Dharminder Chahal is currently the CEO and co-founder of SkylineDx, The Netherlands, developing diagnostic tests in oncology. He is also owner and managing director of Exponential BV in which capacity he acts as consultant to Van Herk Investments. Previously he has held various positions in investment banking and asset management including at Kempen & Co and Robeco.
Ongoing assignments: Board member of BioInvent, Ceradis, Medis Medical Imaging, Sensara and Vitalnext as well as advisory board member of BioGeneration Ventures II, Thuja Capital Fund I and Gilde Healthcare Funds II and III.
Independency: Dharminder Chahal is independent in relation to the company and its senior executives, and dependent in relation to the major shareholders.
Board Member since 2020
MSc, Ph.D. from Lund University
Experience: Helén Tuvesson is a Swedish citizen, born in 1962 and holds a doctor’s degree in cellular and molecular biology in medical science at Lund University. She has more than 25 years of experience from the pharmaceutical industry in various positions within Pharmacia and Active Biotech, including as Chief Scientific Officer at Active Biotech for 6 years. In this role she was responsible for the operational research activities and the company’s project portfolio in late stage clinical development in neurodegenerative diseases and cancer indications. Since 2017, Helén is the CEO of Active Biotech AB.
Ongoing engagement: CEO, Active Biotech AB
Independency: Helén Tuvesson is independent in relation to the company, its senior executives and major shareholders.
Board Member since 2020
MSc from Stockholm School of Economics and Business Administration
Experience: Sven Andreasson is a Swedish citizen, born in 1952 and resides in Washington DC, US. Sven holds a degree in business administration from Stockholm School of Economics and MBA-educations from IMEDE Lausanne, INSEAD Fontainebleau and Ashridge London. Sven Andreasson has broad experience from biotech and pharmaceutical companies. He was CEO of Active Biotech AB 1999-2008, Beta-Cell NV in Belgium 2008-2012 and Isconova AB 2012-2013 where he initiated and completed a sale of the company in 2013 to the American company Novavax. Sven has also held several senior management positions within Pharmacia in Sweden, Germany, Belgium and France. Previous experience from board assignments includes e.g., TiGenix NV, Belgium, Immunicum AB and Cantargia AB as well as Chairman of Erytech SA, France.
Ongoing engagements: Sven is currently working as Senior Vice President of Novavax with responsibility for Business Development. Board member of Cellastra Inc., US and Erytech SA, France.
Independency: Sven Andreasson is independent in relation to the company, its senior executives and major shareholders.